Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
EMERYVILLE, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Bionovo, Inc.
(Nasdaq: BNVI) will present findings on the mechanism of action of its
anti-cancer agent BN107 at the 31st Annual San Antonio Breast Cancer Symposium
being held at the Henry B. Gonzalez Convention Center, San Antonio TX,
December 10-14, 2008.
Bionovo's poster presentation will describe the pathway for cancer cell
apoptosis (cell death) induced by BN107. As explained by Dr. Emma Shtivelman,
Director of Cancer Research at Bionovo, the ability of BN107 to induce cancer
cell death is distinct. BN107 induces apoptosis through the mitochondrial
pathway. BN107 induces death only in estrogen receptor negative breast cancer
cells. Our studies show that cholesterol depletion and disruption of lipid
raft-mediated signaling is most likely responsible for the pro-apoptotic
effect of BN107.
"BN107 mechanism of action and unique selective properties are a result of
some of the biological differences exhibited uniquely by cancer cells. We
believe BN107 will result in better selectivity to hormone independent tumors.
Currently the only available treatment for this group, constituting 40% of
women diagnosed with breast cancer, is chemotherapy. BN107, an oral drug
candidate, should provide a chronic treatment option with a low toxicity
profile," said Dr. Isaac Cohen, Chairman and CEO of Bionovo
Bionovo, Inc.
Bionovo is a pharmaceutical company focused on the discovery and
development of safe and effective treatments for women's health and cancer,
markets with significant unmet needs and billions in potential annual revenue.
The company applies its expertise in the biology of menopause and cancer to
design new drugs derived from botanical sources which have novel mechanisms of
action. Based on the results of early and mid-stage clinical trials, Bionovo
believes they have discovered new classes of drug candidates within their rich
pipeline with the potential to be leaders in their markets. Bionovo is
headquartered in Emeryville, California and is traded on the NASDAQ Capital
Market under the symbol, "BNVI". For more information about Bionovo and its
programs, visit: http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the
business of Bionovo, Inc. that can be identified by the use of forward-looking
terminology such as "believes," "expects," or similar expressions. Such
forward-looking statements involve known and unknown risks and uncertainties,
including uncertainties relating to product development, efficacy and safety,
regulatory actions or delays, the ability to obtain or maintain patent or
other proprietary intellectual property protection, market acceptance,
physician acceptance, third party reimbursement, future capital requirements,
competition in general and other factors that may cause actual results to be
materially different from those described herein as anticipated, believed,
estimated or expected. Certain of these risks and uncertainties are or will be
described in greater detail in our filings with the Securities and Exchange
Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under
no obligation (and expressly disclaims any such obligation) to update or alter
its forward-looking statements whether as a result of new information, future
events or otherwise.
SOURCE Bionovo, Inc.
-0- 12/12/2008
/CONTACT: Claire Fong or Tom Chesterman, both of Bionovo, Inc.,
+1-510-601-2000, investor@bionovo.com /
/Web site: http://www.bionovo.com /
(BNVI)
CO: Bionovo, Inc.
ST: California, Texas
IN: HEA BIO
SU: TDS
HB-AE
-- AQF011 --
8064 12/12/2008 08:00 EST http://www.prnewswire.com
View printer-friendly version